Sugi Predict

Sugi Predict / Compounds / SCHEMBL443066

SCHEMBL443066

SCHEMBL443066

O=c1[nH]c2c(O)ncnc2n1[C@H]1C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TK1 P04183 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ HIF1A Q16665 1/20 0.45
▸ ADORA3 P0DMS8 1/20 0.45
▸ ADORA2A P29274 1/20 0.45
▸ ALOX12 P18054 1/20 0.43
▸ ADRA1A P35348 1/20 0.43
▸ ADRB1 P08588 1/20 0.43
▸ DNMT1 P26358 1/20 0.43
▸ TK2 O00142 1/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ BLM P54132 1/20 0.42
▸ PMP22 Q01453 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5982026 0.88 LMNA (0.45) TK1LMNASMN1; SMN2HIF1AADORA3
SCHEMBL5982032 0.88 LMNA (0.45) TK1LMNASMN1; SMN2HIF1AADORA3
SCHEMBL5982753 0.88 ADORA3 (0.53) TK1LMNASMN1; SMN2HIF1AADORA3
SCHEMBL439799 0.88 ADORA3 (0.53) TK1LMNASMN1; SMN2HIF1AADORA3
SCHEMBL529559 0.88 ADORA3 (0.53) TK1LMNASMN1; SMN2HIF1AADORA3
SCHEMBL27054384 0.88 ADORA3 (0.53) TK1LMNASMN1; SMN2HIF1AADORA3
SCHEMBL5982748 0.88 ADORA3 (0.53) TK1LMNASMN1; SMN2HIF1AADORA3
SCHEMBL439797 0.88 ADORA3 (0.53) TK1LMNASMN1; SMN2HIF1AADORA3
SCHEMBL5983171 0.85 HIF1A (0.44) TK1LMNASMN1; SMN2HIF1AADORA3
SCHEMBL5981933 0.85 HIF1A (0.44) TK1LMNASMN1; SMN2HIF1AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3044228-B1 HIGHLY EFFICIENT SYNTHESIS OF LONG RNA USING REVERSE DIRECTION APPROACH CHEMGENES CORP (US) 2021-04-07 — — EP disclosed
US-10167308-B2 Highly efficient synthesis of long RNA using reverse direction approach CHEMGENES CORPORATION (US) 2019-01-01 — — US disclosed
US-9969764-B2 Dithiolane functionalized nucleoside amidites and supports for stronger immobilization of bio-molecules on solid surfaces CHEMGENES CORPORATION 2018-05-15 — — US disclosed
US-9884885-B2 Synthesis of labile base protected-modified deoxy and modified ribo nucleosides, corresponding phosphoramidites and supports and their use in high purity oligonucleotide synthesis CHEMGENES CORPORATION (US) 2018-02-06 — — US disclosed
US-9605261-B2 RNA synthesis—phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end CHEMGENES CORPORATION (US) 2017-03-28 — — US disclosed
US-20170037076-A1 DITHIOLANE FUNCTIONALIZED NUCLEOSIDE AMIDITES AND SUPPORTS FOR STRONGER IMMOBILIZATION OF BIO-MOLECULES ON SOLID SURFACES CHEMGENES CORPORATION 2017-02-09 — — US disclosed
EP-2326656-B1 RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END CHEMGENES CORP (US) 2017-01-25 — — EP disclosed
EP-3044228-A2 HIGHLY EFFICIENT SYNTHESIS OF LONG RNA USING REVERSE DIRECTION APPROACH Chemgenes Corporation (US) 2016-07-20 — — EP disclosed
US-20160200759-A1 HIGHLY EFFICIENT SYNTHESIS OF LONG RNA USING REVERSE DIRECTION APPROACH CHEMGENES CORPORATION 2016-07-14 — — US disclosed
US-20150218557-A1 RNA SYNTHESIS-PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3'-END CHEMGENES CORPORATION 2015-08-06 — — US disclosed
US-20130072670-A1 RNA SYNTHESIS-PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3'-END CHEMGENES CORPORATION (US) 2013-03-21 — — US disclosed
US-8309707-B2 RNA synthesis-phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end CHEMGENES CORPORATION (US) 2012-11-13 — — US disclosed
US-20120065386-A1 SYNTHESIS OF LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS CHEMGENES CORPORATION 2012-03-15 — — US disclosed
EP-2326656-A2 RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END Chemgenes Corporation (US) 2011-06-01 — — EP disclosed
US-20110015382-A1 Synthesis of N-FMOC protected deoxy nucleosides, ribo nucleosides, modified deoxy and ribo nucleosides, and phosphoramidites, and their use in oligonucleotide synthesis CHEMGENES CORPORATION (US) 2011-01-20 — — US disclosed
US-20100324278-A1 RNA synthesis-phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3'-end CHEMGENES CORPORATION 2010-12-23 — — US disclosed
WO-2010134992-A2 SYNTHESIS LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS CHEMGENES CORPORATION (US) 2010-11-25 — — WO disclosed
WO-2010062404-A2 N-FMOC NUCLEOSIDES AND PHOSPHORAMIDITES, AND OLIGONUCLEOTIDE SYNTHESIS CHEMGENES CORPORATION (US) 2010-06-03 — — WO disclosed
WO-2010027512-A9 RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END CHEMGENES CORPORATION (US) 2010-04-22 — — WO disclosed
WO-2010027512-A2 RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END CHEMGENES CORPORATION (US) 2010-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015382-A1 Synthesis of N-FMOC protected deoxy nucleosides, ribo nucleosides, modified deoxy and ribo nucleosides, and phosphoramidites, and their use in oligonucleotide synthesis RNGTT, RNMT, NSUN2 TK1 816/4885LMNA 911/4885SMN1; SMN2 287/4885
US-20120065386-A1 SYNTHESIS OF LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS RNMT, POLRMT, RNGTT TK1 894/4885LMNA 1822/4885SMN1; SMN2 604/4885
US-20100324278-A1 RNA synthesis-phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3'-end NSUN3, RNMT, NSUN2 TK1 411/4885LMNA 499/4885SMN1; SMN2 1305/4885
US-20130072670-A1 RNA SYNTHESIS-PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3'-END NSUN3, RNMT, NSUN2 TK1 411/4885LMNA 499/4885SMN1; SMN2 1305/4885
US-10167308-B2 Highly efficient synthesis of long RNA using reverse direction approach NSUN3, POLRMT, METTL16 TK1 2840/4885LMNA 1085/4885SMN1; SMN2 617/4885
US-20160200759-A1 HIGHLY EFFICIENT SYNTHESIS OF LONG RNA USING REVERSE DIRECTION APPROACH NSUN3, POLRMT, METTL16 TK1 2840/4885LMNA 1085/4885SMN1; SMN2 617/4885
US-20170037076-A1 DITHIOLANE FUNCTIONALIZED NUCLEOSIDE AMIDITES AND SUPPORTS FOR STRONGER IMMOBILIZATION OF BIO-MOLECULES ON SOLID SURFACES RNGTT, DIMT1, ADAR TK1 104/4885LMNA 3088/4885SMN1; SMN2 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.